Vesigen Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Kendall Sq Ste 001 Bldg 200, Cambridge...Phone Number
(617) 633-7188Website
www.vesigentx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Vesigen Therapeutics
Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology. The company's patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), is expanding the universe of druggable targets by enabling the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells. The team is committed to leveraging ARMMs technology to develop transformative medicines and address currently unmet medical needs.Explore more
Vesigen Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vesigen Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Vesigen Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Vesigen Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Vesigen Therapeutics
Check if Vesigen Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Vesigen Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Vesigen Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Vesigen Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if Vesigen Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Vesigen Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Vesigen Therapeutics
Compare insights from companies similar to Vesigen Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vesigen Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vesigen Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vesigen Therapeutics.
Vesigen Therapeutics Tech Stack
A closer look at the technologies used by Vesigen Therapeutics
Most Recent Scoops
Event
Events
Facilities Relocation / Expansion
Vesigen Therapeutics is planning to move offices in September 2023. The move will impact employees at the existing office located at 790 Memorial Drive, Suite #103, Cambridge, MA.
Executive Move
Board of Directors
New Hire
Executive Move
Thomas Bordner has joined the organization as Senior Director Intellectual Property & Chief Patent Counsel.
Executive Moves, New Hire
New Hire
Executive Move
Vesigen Therapeutics News & Media
Vesigen Receives National Institutes of Health Award in Targeted Genome Editor Delivery Challenge
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #ARMMs--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, was selected as a Phase 1 winner of the National Institutes of Health TARGETED (Targeted Genome Editor Delivery) Challenge. The Company’s proposal, “Engineered ARMMs: Promising Human-Derived Vectors for Cell Type-Specific Delivery of Genome Editors”, builds on recent data demonstrating directed tropisVesigen Highlights Data Demonstrating Directed Tropism of Non-Viral Delivery Platform at the 30th Annual Congress of the European Society of Gene & Cell Therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #ARMMs--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today presented data highlighting the potential of the Company’s non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) technology to overcome fundamental delivery challenges that limit the clinical application of emerging treatment modalities. Data highlighted the first demonstration of cell type-Vesigen Highlights Non-Human Primate Biodistribution of Non-Viral Technology and Functional Delivery of Genome Editors In Vivo at the Cracking the Code: The Dawn of Nucleic Acid Medicines Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #crackingthecode23--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, presented data further highlighting the potential of the Company’s non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) technology to deliver novel therapeutic payloads to cell and tissue types relevant to multiple therapeutic areas with high unmet need. Specifically, the Company presVesigen to Present at the 2023 Cell and Gene Meeting on the Mesa
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that Paulash Mohsen, Chief Executive Officer, will present at the 2023 Cell and Gene Meeting on the Mesa on October 12 at 9:15 AM PT in Carlsbad, CA. A livestream of the presentation will be available to registered attendees within the conference virtual platform. About Vesigen Therapeutics Ve
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vesigen Therapeutics
Sign Up For FreeTo access detailed company insights
Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology. The company's patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), is expanding the universe of druggable targets by enabling the delivery of a wide range of... Read More
